High-grade XXXX and @entity585 .

@entity1 @entity263 @entity586 @entity585 @entity5 @entity10831
@entity263 is the most common @entity5 in @entity1 . Encouraging results are emerging in @entity263 risk reduction with @entity10831 (5AR) inhibitors. The @entity263 Prevention Trial (PCPT) showed that @entity263 risk is reduced by @entity585 . However, there was an increase in the incidence of high-grade @entity263 with @entity585 treatment vs placebo. The number of cases should have increased during the study in the @entity585 group with the length of exposure to the drug. But, in fact the ratio between the two groups was lower during the fourth year. This therefore favours the hypothesis of a bias in the results. There are many hypotheses to explain the increase in the prevalence of high-grade @entity5 with @entity585 therapy. The effects of @entity585 on prostate volume rather than on the @entity5 's morphology and a selective inhibition of low-grade @entity5 may have contributed to the increase the number of high-grade @entity5 with @entity585 in the PCPT. Despite the current trend to explain the increase of high-grade @entity5 with @entity585 therapy by a detection bias, other studies underline the potential role of low levels of @entity586 in the genesis of high-grade @entity5 . In May 2008, a re-analysis of the PCPT results showed a significant decrease of 30% in the overall risk of @entity263 in the @entity585 group vs the placebo group, but it also found a statistically non-significant and less important increase of the prevalence of high-grade @entity5 in the @entity585 group. However, the 5AR isoenzyme type 1 is present at higher rates than type 2 in high-grade @entity5 . Thus, @entity585 is probably not the ideal drug to prevent high-grade @entity5 .
